http://new.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Fri, 07 Aug 2026 09:09:16 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://new.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Analyst+PT+Change/Odyssey+Therapeutics+%28ODTX%29+PT+Raised+to+%2429+at+JPMorgan/26888358.html JPMorgan analyst Brian Cheng raised the price target on Odyssey Therapeutics (NASDAQ: ODTX) to $29.00 (from $26.00) while maintaining a Overweight rating. http://www.streetinsider.com/Analyst+PT+Change/Odyssey+Therapeutics+%28ODTX%29+PT+Raised+to+%2429+at+JPMorgan/26888358.html Fri, 07 Aug 2026 09:09:16 -0400 ODTX http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Odyssey+Therapeutics%2C+++++For%3A+Jun+30/26877483.html si-local-file:///var/storage/secattach/20260806/26877483.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Odyssey+Therapeutics%2C+++++For%3A+Jun+30/26877483.html Thu, 06 Aug 2026 06:03:00 -0400 O.55938090 ODTX http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Odyssey+Therapeutics%2C+++++For%3A+Jun+30/26877483.html si-local-file:///var/storage/secattach/20260806/26877483.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Odyssey+Therapeutics%2C+++++For%3A+Jun+30/26877483.html Thu, 06 Aug 2026 06:03:00 -0400 O.55938090 ODTX http://www.streetinsider.com/Corporate+News/Evotec+and+Odyssey+partner+on+autoimmune+drug+discovery/26877309.html <p>Evotec SE (NASDAQ: EVO) and Odyssey Therapeutics, Inc. (NASDAQ: ODTX) have entered an R&D collaboration to discover small molecule drug candidates for autoimmune and inflammatory diseases, according to a press release from Evotec.</p><p>Under the agreement, Odyssey will use Evotec's discovery platform, screening capabilities, and AI-enabled data science tools to identify and validate drug candidates across multiple disease targets. The collaboration pairs Odyssey's disease biology expertise with Evotec's compound libraries and high-throughput experimentation capabilities.</p><p>Evotec is eligible to receive milestone payments tied to the delivery of validated hit series for each target. Detailed financial terms were not disclosed.</p><p>Evotec Chief Scientific Officer Dr. http://www.streetinsider.com/Corporate+News/Evotec+and+Odyssey+partner+on+autoimmune+drug+discovery/26877309.html Thu, 06 Aug 2026 06:00:24 -0400 EVO EVT ODTX http://www.streetinsider.com/Corporate+News/Evotec+and+Odyssey+partner+on+autoimmune+drug+discovery/26877309.html <p>Evotec SE (NASDAQ: EVO) and Odyssey Therapeutics, Inc. (NASDAQ: ODTX) have entered an R&D collaboration to discover small molecule drug candidates for autoimmune and inflammatory diseases, according to a press release from Evotec.</p><p>Under the agreement, Odyssey will use Evotec's discovery platform, screening capabilities, and AI-enabled data science tools to identify and validate drug candidates across multiple disease targets. The collaboration pairs Odyssey's disease biology expertise with Evotec's compound libraries and high-throughput experimentation capabilities.</p><p>Evotec is eligible to receive milestone payments tied to the delivery of validated hit series for each target. Detailed financial terms were not disclosed.</p><p>Evotec Chief Scientific Officer Dr. http://www.streetinsider.com/Corporate+News/Evotec+and+Odyssey+partner+on+autoimmune+drug+discovery/26877309.html Thu, 06 Aug 2026 06:00:24 -0400 EVO EVT ODTX http://www.streetinsider.com/Corporate+News/Evotec+and+Odyssey+partner+on+autoimmune+drug+discovery/26877309.html <p>Evotec SE (NASDAQ: EVO) and Odyssey Therapeutics, Inc. (NASDAQ: ODTX) have entered an R&D collaboration to discover small molecule drug candidates for autoimmune and inflammatory diseases, according to a press release from Evotec.</p><p>Under the agreement, Odyssey will use Evotec's discovery platform, screening capabilities, and AI-enabled data science tools to identify and validate drug candidates across multiple disease targets. The collaboration pairs Odyssey's disease biology expertise with Evotec's compound libraries and high-throughput experimentation capabilities.</p><p>Evotec is eligible to receive milestone payments tied to the delivery of validated hit series for each target. Detailed financial terms were not disclosed.</p><p>Evotec Chief Scientific Officer Dr. http://www.streetinsider.com/Corporate+News/Evotec+and+Odyssey+partner+on+autoimmune+drug+discovery/26877309.html Thu, 06 Aug 2026 06:00:24 -0400 EVO EVT ODTX http://www.streetinsider.com/Press+Releases/Evotec+and+Odyssey+Therapeutics+Enter+AI-Enabled+R%26amp%3BD+Collaboration+in+Autoimmune+and+Inflammatory+Diseases/26876812.html <div class="xn-content"> <ul type="disc"><li>Collaboration combines Odyssey's disease biology expertise with Evotec's AI-enabled discovery platform, advanced screening capabilities and proprietary compound libraries to support advancement of Odyssey's discovery-stage programs</li><li>Evotec to deliver validated hit series across multiple high-value targets for large inflammatory and autoimmune diseases with high unmet medical need</li></ul><p><span class="legendSpanClass"><location value="LU/de..hambrg" idsrc="xmltag.org" >HAMBURG, Germany</location></span>, <span class="legendSpanClass"><chron>Aug. 6, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:EVO" idsrc="xmltag.org" >Evotec SE</span> (NASDAQ: EVO) (Frankfurt Prime Standard: EVT) today announced that it has entered a strategic R&amp;D collaboration with <span value="NASDAQ-NMS:ODTX" idsrc="xmltag.org" >Odyssey Therapeutics, Inc.</span> (NASDAQ: ODTX) to discover potential new treatments in autoimmune and inflammatory diseases.</p> <p>Under the agreement, http://www.streetinsider.com/Press+Releases/Evotec+and+Odyssey+Therapeutics+Enter+AI-Enabled+R%26amp%3BD+Collaboration+in+Autoimmune+and+Inflammatory+Diseases/26876812.html Thu, 06 Aug 2026 02:16:00 -0400 EVO EVT O.00233944 O.55938090 ODTX http://www.streetinsider.com/Press+Releases/Evotec+and+Odyssey+Therapeutics+Enter+AI-Enabled+R%26amp%3BD+Collaboration+in+Autoimmune+and+Inflammatory+Diseases/26876812.html <div class="xn-content"> <ul type="disc"><li>Collaboration combines Odyssey's disease biology expertise with Evotec's AI-enabled discovery platform, advanced screening capabilities and proprietary compound libraries to support advancement of Odyssey's discovery-stage programs</li><li>Evotec to deliver validated hit series across multiple high-value targets for large inflammatory and autoimmune diseases with high unmet medical need</li></ul><p><span class="legendSpanClass"><location value="LU/de..hambrg" idsrc="xmltag.org" >HAMBURG, Germany</location></span>, <span class="legendSpanClass"><chron>Aug. 6, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:EVO" idsrc="xmltag.org" >Evotec SE</span> (NASDAQ: EVO) (Frankfurt Prime Standard: EVT) today announced that it has entered a strategic R&amp;D collaboration with <span value="NASDAQ-NMS:ODTX" idsrc="xmltag.org" >Odyssey Therapeutics, Inc.</span> (NASDAQ: ODTX) to discover potential new treatments in autoimmune and inflammatory diseases.</p> <p>Under the agreement, http://www.streetinsider.com/Press+Releases/Evotec+and+Odyssey+Therapeutics+Enter+AI-Enabled+R%26amp%3BD+Collaboration+in+Autoimmune+and+Inflammatory+Diseases/26876812.html Thu, 06 Aug 2026 02:16:00 -0400 EVO EVT O.00233944 O.55938090 ODTX http://www.streetinsider.com/Press+Releases/Evotec+and+Odyssey+Therapeutics+Enter+AI-Enabled+R%26amp%3BD+Collaboration+in+Autoimmune+and+Inflammatory+Diseases/26876812.html <div class="xn-content"> <ul type="disc"><li>Collaboration combines Odyssey's disease biology expertise with Evotec's AI-enabled discovery platform, advanced screening capabilities and proprietary compound libraries to support advancement of Odyssey's discovery-stage programs</li><li>Evotec to deliver validated hit series across multiple high-value targets for large inflammatory and autoimmune diseases with high unmet medical need</li></ul><p><span class="legendSpanClass"><location value="LU/de..hambrg" idsrc="xmltag.org" >HAMBURG, Germany</location></span>, <span class="legendSpanClass"><chron>Aug. 6, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:EVO" idsrc="xmltag.org" >Evotec SE</span> (NASDAQ: EVO) (Frankfurt Prime Standard: EVT) today announced that it has entered a strategic R&amp;D collaboration with <span value="NASDAQ-NMS:ODTX" idsrc="xmltag.org" >Odyssey Therapeutics, Inc.</span> (NASDAQ: ODTX) to discover potential new treatments in autoimmune and inflammatory diseases.</p> <p>Under the agreement, http://www.streetinsider.com/Press+Releases/Evotec+and+Odyssey+Therapeutics+Enter+AI-Enabled+R%26amp%3BD+Collaboration+in+Autoimmune+and+Inflammatory+Diseases/26876812.html Thu, 06 Aug 2026 02:16:00 -0400 EVO EVT O.00233944 O.55938090 ODTX http://www.streetinsider.com/Press+Releases/Evotec+and+Odyssey+Therapeutics+Enter+AI-Enabled+R%26amp%3BD+Collaboration+in+Autoimmune+and+Inflammatory+Diseases/26876812.html <div class="xn-content"> <ul type="disc"><li>Collaboration combines Odyssey's disease biology expertise with Evotec's AI-enabled discovery platform, advanced screening capabilities and proprietary compound libraries to support advancement of Odyssey's discovery-stage programs</li><li>Evotec to deliver validated hit series across multiple high-value targets for large inflammatory and autoimmune diseases with high unmet medical need</li></ul><p><span class="legendSpanClass"><location value="LU/de..hambrg" idsrc="xmltag.org" >HAMBURG, Germany</location></span>, <span class="legendSpanClass"><chron>Aug. 6, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:EVO" idsrc="xmltag.org" >Evotec SE</span> (NASDAQ: EVO) (Frankfurt Prime Standard: EVT) today announced that it has entered a strategic R&amp;D collaboration with <span value="NASDAQ-NMS:ODTX" idsrc="xmltag.org" >Odyssey Therapeutics, Inc.</span> (NASDAQ: ODTX) to discover potential new treatments in autoimmune and inflammatory diseases.</p> <p>Under the agreement, http://www.streetinsider.com/Press+Releases/Evotec+and+Odyssey+Therapeutics+Enter+AI-Enabled+R%26amp%3BD+Collaboration+in+Autoimmune+and+Inflammatory+Diseases/26876812.html Thu, 06 Aug 2026 02:16:00 -0400 EVO EVT O.00233944 O.55938090 ODTX http://www.streetinsider.com/Press+Releases/Evotec+and+Odyssey+Therapeutics+Enter+AI-Enabled+R%26amp%3BD+Collaboration+in+Autoimmune+and+Inflammatory+Diseases/26876812.html <div class="xn-content"> <ul type="disc"><li>Collaboration combines Odyssey's disease biology expertise with Evotec's AI-enabled discovery platform, advanced screening capabilities and proprietary compound libraries to support advancement of Odyssey's discovery-stage programs</li><li>Evotec to deliver validated hit series across multiple high-value targets for large inflammatory and autoimmune diseases with high unmet medical need</li></ul><p><span class="legendSpanClass"><location value="LU/de..hambrg" idsrc="xmltag.org" >HAMBURG, Germany</location></span>, <span class="legendSpanClass"><chron>Aug. 6, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:EVO" idsrc="xmltag.org" >Evotec SE</span> (NASDAQ: EVO) (Frankfurt Prime Standard: EVT) today announced that it has entered a strategic R&amp;D collaboration with <span value="NASDAQ-NMS:ODTX" idsrc="xmltag.org" >Odyssey Therapeutics, Inc.</span> (NASDAQ: ODTX) to discover potential new treatments in autoimmune and inflammatory diseases.</p> <p>Under the agreement, http://www.streetinsider.com/Press+Releases/Evotec+and+Odyssey+Therapeutics+Enter+AI-Enabled+R%26amp%3BD+Collaboration+in+Autoimmune+and+Inflammatory+Diseases/26876812.html Thu, 06 Aug 2026 02:16:00 -0400 EVO EVT O.00233944 O.55938090 ODTX http://www.streetinsider.com/PRNewswire/Evotec+and+Odyssey+Therapeutics+Enter+AI-Enabled+R%26amp%3BD+Collaboration+in+Autoimmune+and+Inflammatory+Diseases/26876812.html <div class="xn-content"> <ul type="disc"><li>Collaboration combines Odyssey's disease biology expertise with Evotec's AI-enabled discovery platform, advanced screening capabilities and proprietary compound libraries to support advancement of Odyssey's discovery-stage programs</li><li>Evotec to deliver validated hit series across multiple high-value targets for large inflammatory and autoimmune diseases with high unmet medical need</li></ul><p><span class="legendSpanClass"><location value="LU/de..hambrg" idsrc="xmltag.org" >HAMBURG, Germany</location></span>, <span class="legendSpanClass"><chron>Aug. 6, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:EVO" idsrc="xmltag.org" >Evotec SE</span> (NASDAQ: EVO) (Frankfurt Prime Standard: EVT) today announced that it has entered a strategic R&amp;D collaboration with <span value="NASDAQ-NMS:ODTX" idsrc="xmltag.org" >Odyssey Therapeutics, Inc.</span> (NASDAQ: ODTX) to discover potential new treatments in autoimmune and inflammatory diseases.</p> <p>Under the agreement, http://www.streetinsider.com/PRNewswire/Evotec+and+Odyssey+Therapeutics+Enter+AI-Enabled+R%26amp%3BD+Collaboration+in+Autoimmune+and+Inflammatory+Diseases/26876812.html Thu, 06 Aug 2026 02:16:00 -0400 EVO EVT O.00233944 O.55938090 ODTX http://www.streetinsider.com/PRNewswire/Evotec+and+Odyssey+Therapeutics+Enter+AI-Enabled+R%26amp%3BD+Collaboration+in+Autoimmune+and+Inflammatory+Diseases/26876812.html <div class="xn-content"> <ul type="disc"><li>Collaboration combines Odyssey's disease biology expertise with Evotec's AI-enabled discovery platform, advanced screening capabilities and proprietary compound libraries to support advancement of Odyssey's discovery-stage programs</li><li>Evotec to deliver validated hit series across multiple high-value targets for large inflammatory and autoimmune diseases with high unmet medical need</li></ul><p><span class="legendSpanClass"><location value="LU/de..hambrg" idsrc="xmltag.org" >HAMBURG, Germany</location></span>, <span class="legendSpanClass"><chron>Aug. 6, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:EVO" idsrc="xmltag.org" >Evotec SE</span> (NASDAQ: EVO) (Frankfurt Prime Standard: EVT) today announced that it has entered a strategic R&amp;D collaboration with <span value="NASDAQ-NMS:ODTX" idsrc="xmltag.org" >Odyssey Therapeutics, Inc.</span> (NASDAQ: ODTX) to discover potential new treatments in autoimmune and inflammatory diseases.</p> <p>Under the agreement, http://www.streetinsider.com/PRNewswire/Evotec+and+Odyssey+Therapeutics+Enter+AI-Enabled+R%26amp%3BD+Collaboration+in+Autoimmune+and+Inflammatory+Diseases/26876812.html Thu, 06 Aug 2026 02:16:00 -0400 EVO EVT O.00233944 O.55938090 ODTX http://www.streetinsider.com/PRNewswire/Evotec+and+Odyssey+Therapeutics+Enter+AI-Enabled+R%26amp%3BD+Collaboration+in+Autoimmune+and+Inflammatory+Diseases/26876812.html <div class="xn-content"> <ul type="disc"><li>Collaboration combines Odyssey's disease biology expertise with Evotec's AI-enabled discovery platform, advanced screening capabilities and proprietary compound libraries to support advancement of Odyssey's discovery-stage programs</li><li>Evotec to deliver validated hit series across multiple high-value targets for large inflammatory and autoimmune diseases with high unmet medical need</li></ul><p><span class="legendSpanClass"><location value="LU/de..hambrg" idsrc="xmltag.org" >HAMBURG, Germany</location></span>, <span class="legendSpanClass"><chron>Aug. 6, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:EVO" idsrc="xmltag.org" >Evotec SE</span> (NASDAQ: EVO) (Frankfurt Prime Standard: EVT) today announced that it has entered a strategic R&amp;D collaboration with <span value="NASDAQ-NMS:ODTX" idsrc="xmltag.org" >Odyssey Therapeutics, Inc.</span> (NASDAQ: ODTX) to discover potential new treatments in autoimmune and inflammatory diseases.</p> <p>Under the agreement, http://www.streetinsider.com/PRNewswire/Evotec+and+Odyssey+Therapeutics+Enter+AI-Enabled+R%26amp%3BD+Collaboration+in+Autoimmune+and+Inflammatory+Diseases/26876812.html Thu, 06 Aug 2026 02:16:00 -0400 EVO EVT O.00233944 O.55938090 ODTX http://www.streetinsider.com/PRNewswire/Evotec+and+Odyssey+Therapeutics+Enter+AI-Enabled+R%26amp%3BD+Collaboration+in+Autoimmune+and+Inflammatory+Diseases/26876812.html <div class="xn-content"> <ul type="disc"><li>Collaboration combines Odyssey's disease biology expertise with Evotec's AI-enabled discovery platform, advanced screening capabilities and proprietary compound libraries to support advancement of Odyssey's discovery-stage programs</li><li>Evotec to deliver validated hit series across multiple high-value targets for large inflammatory and autoimmune diseases with high unmet medical need</li></ul><p><span class="legendSpanClass"><location value="LU/de..hambrg" idsrc="xmltag.org" >HAMBURG, Germany</location></span>, <span class="legendSpanClass"><chron>Aug. 6, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:EVO" idsrc="xmltag.org" >Evotec SE</span> (NASDAQ: EVO) (Frankfurt Prime Standard: EVT) today announced that it has entered a strategic R&amp;D collaboration with <span value="NASDAQ-NMS:ODTX" idsrc="xmltag.org" >Odyssey Therapeutics, Inc.</span> (NASDAQ: ODTX) to discover potential new treatments in autoimmune and inflammatory diseases.</p> <p>Under the agreement, http://www.streetinsider.com/PRNewswire/Evotec+and+Odyssey+Therapeutics+Enter+AI-Enabled+R%26amp%3BD+Collaboration+in+Autoimmune+and+Inflammatory+Diseases/26876812.html Thu, 06 Aug 2026 02:16:00 -0400 EVO EVT O.00233944 O.55938090 ODTX http://www.streetinsider.com/PRNewswire/Evotec+and+Odyssey+Therapeutics+Enter+AI-Enabled+R%26amp%3BD+Collaboration+in+Autoimmune+and+Inflammatory+Diseases/26876812.html <div class="xn-content"> <ul type="disc"><li>Collaboration combines Odyssey's disease biology expertise with Evotec's AI-enabled discovery platform, advanced screening capabilities and proprietary compound libraries to support advancement of Odyssey's discovery-stage programs</li><li>Evotec to deliver validated hit series across multiple high-value targets for large inflammatory and autoimmune diseases with high unmet medical need</li></ul><p><span class="legendSpanClass"><location value="LU/de..hambrg" idsrc="xmltag.org" >HAMBURG, Germany</location></span>, <span class="legendSpanClass"><chron>Aug. 6, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:EVO" idsrc="xmltag.org" >Evotec SE</span> (NASDAQ: EVO) (Frankfurt Prime Standard: EVT) today announced that it has entered a strategic R&amp;D collaboration with <span value="NASDAQ-NMS:ODTX" idsrc="xmltag.org" >Odyssey Therapeutics, Inc.</span> (NASDAQ: ODTX) to discover potential new treatments in autoimmune and inflammatory diseases.</p> <p>Under the agreement, http://www.streetinsider.com/PRNewswire/Evotec+and+Odyssey+Therapeutics+Enter+AI-Enabled+R%26amp%3BD+Collaboration+in+Autoimmune+and+Inflammatory+Diseases/26876812.html Thu, 06 Aug 2026 02:16:00 -0400 EVO EVT O.00233944 O.55938090 ODTX http://www.streetinsider.com/Press+Releases/Odyssey+Therapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Corporate+Update/26861220.html <p align="center"><em>Data from the Phase 2a monotherapy trial of OD-001 accepted for oral presentation at United European Gastroenterology Week in October</em></p> <p align="center"><em>Phase 2a combination trial of OD-001 with vedolizumab and Phase 2b monotherapy trial of OD-001 expected to initiate in 2H 2026</em></p> <p align="center"><em>Cash on hand as of June 30, 2026 of $433.1M expected to fund operations into the second half of 2028</em></p> <p>BOSTON, Aug. 04, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=jUQkEEhlVnTCxdjDJr3zT_ZYcPqPQ34-iVG0RyKUIVGxFVSP_Wx5qaXXpSUZ0HDwlDQZa5LPsUWmYIsmbD8idS-2KrlI1hwGTXkPLE6TePs=" rel="nofollow" target="_blank">Odyssey Therapeutics, Inc.</a> (Nasdaq: ODTX) (“Odyssey” or the “Company”), a clinical-stage biopharmaceutical company seeking to transform the standard of care for http://www.streetinsider.com/Press+Releases/Odyssey+Therapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Corporate+Update/26861220.html Tue, 04 Aug 2026 07:00:00 -0400 ODTX http://www.streetinsider.com/Globe+Newswire/Odyssey+Therapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Corporate+Update/26861220.html <p align="center"><em>Data from the Phase 2a monotherapy trial of OD-001 accepted for oral presentation at United European Gastroenterology Week in October</em></p> <p align="center"><em>Phase 2a combination trial of OD-001 with vedolizumab and Phase 2b monotherapy trial of OD-001 expected to initiate in 2H 2026</em></p> <p align="center"><em>Cash on hand as of June 30, 2026 of $433.1M expected to fund operations into the second half of 2028</em></p> <p>BOSTON, Aug. 04, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=jUQkEEhlVnTCxdjDJr3zT_ZYcPqPQ34-iVG0RyKUIVGxFVSP_Wx5qaXXpSUZ0HDwlDQZa5LPsUWmYIsmbD8idS-2KrlI1hwGTXkPLE6TePs=" rel="nofollow" target="_blank">Odyssey Therapeutics, Inc.</a> (Nasdaq: ODTX) (“Odyssey” or the “Company”), a clinical-stage biopharmaceutical company seeking to transform the standard of care for http://www.streetinsider.com/Globe+Newswire/Odyssey+Therapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Corporate+Update/26861220.html Tue, 04 Aug 2026 07:00:00 -0400 ODTX http://www.streetinsider.com/Press+Releases/Odyssey+Therapeutics+Reports+First+Quarter+2026+Financial+Results+and+Provides+Corporate+Update/26660058.html <p align="center"><em>Reported positive clinical proof-of-concept data for OD-001, our first-in-class, oral RIPK2 scaffolding inhibitor, in a Phase 2a monotherapy trial for moderate to severe ulcerative colitis</em></p> <p align="center"><em>Cash on hand as of March 31, 2026, together with net proceeds from the IPO, and concurrent private placement, of $464M expected to fund operations into the second half of 2028</em></p> <p>BOSTON, June 17, 2026 (GLOBE NEWSWIRE) -- Odyssey Therapeutics, Inc. (Nasdaq: ODTX) (“Odyssey” or the “Company”), a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients suffering from autoimmune and inflammatory diseases by developing medicines http://www.streetinsider.com/Press+Releases/Odyssey+Therapeutics+Reports+First+Quarter+2026+Financial+Results+and+Provides+Corporate+Update/26660058.html Wed, 17 Jun 2026 16:15:00 -0400 ODTX http://www.streetinsider.com/Globe+Newswire/Odyssey+Therapeutics+Reports+First+Quarter+2026+Financial+Results+and+Provides+Corporate+Update/26660058.html <p align="center"><em>Reported positive clinical proof-of-concept data for OD-001, our first-in-class, oral RIPK2 scaffolding inhibitor, in a Phase 2a monotherapy trial for moderate to severe ulcerative colitis</em></p> <p align="center"><em>Cash on hand as of March 31, 2026, together with net proceeds from the IPO, and concurrent private placement, of $464M expected to fund operations into the second half of 2028</em></p> <p>BOSTON, June 17, 2026 (GLOBE NEWSWIRE) -- Odyssey Therapeutics, Inc. (Nasdaq: ODTX) (“Odyssey” or the “Company”), a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients suffering from autoimmune and inflammatory diseases by developing medicines http://www.streetinsider.com/Globe+Newswire/Odyssey+Therapeutics+Reports+First+Quarter+2026+Financial+Results+and+Provides+Corporate+Update/26660058.html Wed, 17 Jun 2026 16:15:00 -0400 ODTX http://www.streetinsider.com/New+Coverage/Wedbush+Starts+Odyssey+Therapeutics+%28ODTX%29+at+Outperform/26587106.html <p>Wedbush analyst David Nierengarten initiates coverage on Odyssey Therapeutics (NASDAQ: ODTX) with a Outperform rating and a price target of $30.00.</p><p>For an analyst ratings summary and ratings history on Odyssey Therapeutics <a href="http://www.streetinsider.com/rating_history.php?q=ODTX">click here</a>. For more ratings news on Odyssey Therapeutics <a href="http://www.streetinsider.com/stock_lookup_news.php?q=ODTX&amp;type=analyst">click here</a>.</p><p>Shares of Odyssey Therapeutics closed at $16.96 yesterday.</p> http://www.streetinsider.com/New+Coverage/Wedbush+Starts+Odyssey+Therapeutics+%28ODTX%29+at+Outperform/26587106.html Tue, 02 Jun 2026 06:59:50 -0400 ODTX http://www.streetinsider.com/New+Coverage/Oppenheimer+Starts+Odyssey+Therapeutics+%28ODTX%29+at+Outperform/26586517.html (Updated - June 2, 2026 6:07 AM EDT) <p>Oppenheimer initiates coverage on Odyssey Therapeutics (NASDAQ: ODTX) with a Outperform rating and a price target of $40.00.</p><p>The analyst comments "We are initiating coverage of ODTX with an Outperform rating and $40 PT following the completion of the company's initial public offering on May 8th. The company's lead candidate, OD-001, has demonstrated clinical proof-of-concept in ulcerative colitis (UC), and represents a differentiated asset in the ~$10B UC space, given its novel mechanism (targeting RIPK2) and oral profile, with additional potential upside in CD. ODTX's pipeline includes other promising candidates, targeting SLC15A4 and TNFR2, http://www.streetinsider.com/New+Coverage/Oppenheimer+Starts+Odyssey+Therapeutics+%28ODTX%29+at+Outperform/26586517.html Tue, 02 Jun 2026 06:07:51 -0400 ODTX http://www.streetinsider.com/Analyst+Comments/Oppenheimer+Starts+Odyssey+Therapeutics+%28ODTX%29+at+Outperform/26586517.html (Updated - June 2, 2026 6:07 AM EDT) <p>Oppenheimer initiates coverage on Odyssey Therapeutics (NASDAQ: ODTX) with a Outperform rating and a price target of $40.00.</p><p>The analyst comments "We are initiating coverage of ODTX with an Outperform rating and $40 PT following the completion of the company's initial public offering on May 8th. The company's lead candidate, OD-001, has demonstrated clinical proof-of-concept in ulcerative colitis (UC), and represents a differentiated asset in the ~$10B UC space, given its novel mechanism (targeting RIPK2) and oral profile, with additional potential upside in CD. ODTX's pipeline includes other promising candidates, targeting SLC15A4 and TNFR2, http://www.streetinsider.com/Analyst+Comments/Oppenheimer+Starts+Odyssey+Therapeutics+%28ODTX%29+at+Outperform/26586517.html Tue, 02 Jun 2026 06:07:51 -0400 ODTX http://www.streetinsider.com/New+Coverage/Cantor+Fitzgerald+Starts+Odyssey+Therapeutics+%28ODTX%29+at+Overweight/26586618.html <p>Cantor Fitzgerald analyst Eric Schmidt initiates coverage on Odyssey Therapeutics (NASDAQ: ODTX) with a Overweight rating.</p><p>For an analyst ratings summary and ratings history on Odyssey Therapeutics <a href="http://www.streetinsider.com/rating_history.php?q=ODTX">click here</a>. For more ratings news on Odyssey Therapeutics <a href="http://www.streetinsider.com/stock_lookup_news.php?q=ODTX&amp;type=analyst">click here</a>.</p><p>Shares of Odyssey Therapeutics closed at $16.96 yesterday.</p> http://www.streetinsider.com/New+Coverage/Cantor+Fitzgerald+Starts+Odyssey+Therapeutics+%28ODTX%29+at+Overweight/26586618.html Tue, 02 Jun 2026 06:04:43 -0400 ODTX http://www.streetinsider.com/New+Coverage/TD+Cowen+Starts+Odyssey+Therapeutics+%28ODTX%29+at+Buy/26586317.html <p>TD Cowen analyst Tyler Van Buren initiates coverage on Odyssey Therapeutics (NASDAQ: ODTX) with a Buy rating.</p><p>The analyst comments "Odyssey is pursuing novel biology for large I&I markets with world-class management; we initiate at Buy. The lead oral RIPK2i for UC generated a 27% clinical remission rate, which held up at 25% in treatment-experienced patients & is a result of the upstream MoA. The SCL15A4 inhibitor for B-cell autoimmune disease & TNFR2 agonist for I&I are also intriguing, offering significant potential upside."</p><p>For an analyst ratings summary and ratings history on Odyssey Therapeutics <a href="http://www.streetinsider.com/rating_history.php?q=ODTX">click here</a>. For more ratings news on http://www.streetinsider.com/New+Coverage/TD+Cowen+Starts+Odyssey+Therapeutics+%28ODTX%29+at+Buy/26586317.html Tue, 02 Jun 2026 05:34:08 -0400 ODTX